Do we still need the aminoglycosides?

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 201-205

  Durante Mangoni, Emanuele ^a   Grammatikos, Alexandros ^b,c   Utili, Riccardo ^a   Falagas, Matthew E ^b,d,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Antibiotics; Gram negative bacteria; Infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIOXIDANT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; DAPTOMYCIN; GENTAMICIN; HABEKACIN; ISEPAMICIN; NEOMYCIN; NETILMICIN; PAROMOMYCIN; PENICILLIN G; POLYASPARTIC ACID; SPECTINOMYCIN; STREPTOMYCIN; TOBRAMYCIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATION; BRUCELLOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BINDING; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TRANSPORT; DRUG URINE LEVEL; ENDOCARDITIS; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NONHUMAN; OTOTOXICITY; PHYSICIAN; PLAGUE; PRIORITY JOURNAL; PROTOZOAL INFECTION; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; TREMOR; TUBERCULOSIS; TULAREMIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 60349103085     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.09.001     Document Type: Short Survey

References (40)

1. Fourmy D., Recht M.I., Blanchard S.C., and Puglisi J.D. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274 (1996) 1367-1371
2. Mingeot-Leclercq M.P., Glupczynski Y., and Tulkens P.M. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43 (1999) 727-737
3. Allan J.D., and Moellering Jr. R.C. Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations. Rev Infect Dis 7 Suppl 4 (1985) S559-S571
4. Novelli A., Mazzei T., Fallani S., Cassetta M.I., and Conti S. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. J Chemother 7 (1995) 355-362
5. Davies J., and Wright G.D. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 5 (1997) 234-240
6. Daigle D.M., McKay G.A., and Wright G.D. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 272 (1997) 24755-24758
7. Hon W.C., McKay G.A., Thompson P.R., Sweet R.M., Yang D.S., Wright G.D., et al. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 89 (1997) 887-895
8. Doi Y., and Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 45 (2007) 88-94
9. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 479-487
10. Westbrock-Wadman S., Sherman D.R., Hickey M.J., Coulter S.N., Zhu Y.Q., Warrener P., et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 43 (1999) 2975-2983
11. Yokoyama K., Doi Y., Yamane K., Kurokawa H., Shibata N., Shibayama K., et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362 (2003) 1888-1893
12. McLean A.J., IoannidesDemos L.L., Li S.C., Bastone E.B., and Spicer W.J. Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses. J Antimicrob Chemother 32 (1993) 301-305
13. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10 [Quiz 11-12]
14. Freeman C.D., Nicolau D.P., Belliveau P.P., and Nightingale C.H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39 (1997) 677-686
15. Tam V.H., Kabbara S., Vo G., Schilling A.N., and Coyle E.A. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006) 2626-2631
16. Baddour L.M., Wilson W.R., Bayer A.S., Fowler Jr. V.G., Bolger A.F., Levison M.E., et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111 (2005) e394-e434
17. Drusano G.L., Ambrose P.G., Bhavnani S.M., Bertino J.S., Nafziger A.N., and Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45 (2007) 753-760
18. Bliziotis I.A., Samonis G., Vardakas K.Z., Chrysanthopoulou S., and Falagas M.E. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41 (2005) 149-158
19. Falagas M.E., Matthaiou D.K., and Bliziotis I.A. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57 (2006) 639-647
20. Falagas M.E., Matthaiou D.K., Karveli E.A., and Peppas G. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 25 (2007) 537-556
21. Leibovici L., Paul M., Poznanski O., Drucker M., Samra Z., Konigsberger H., et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 41 (1997) 1127-1133
22. Paul M., Silbiger I., Grozinsky S., Soares-Weiser K., and Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1 (2006) CD003344
23. Paul M., Soares-Weiser K., and Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326 (2003) 1111
24. Vidal L., Gafter-Gvili A., Borok S., Fraser A., Leibovici L., and Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 60 (2007) 247-257
25. Panidis D., Markantonis S.L., Boutzouka E., Karatzas S., and Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128 (2005) 545-552
26. Mandell L. Treatment of community-acquired pneumonia down under versus the United States: is it really that different?. Clin Infect Dis 46 (2008) 1522-1524
27. Sader H.S., Biedenbach D.J., and Jones R.N. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 47 (2003) 361-364
28. Vargas L.J., Casselas J.M., Gales A., Tomé G., Sader H.S., Lanza A., et al. Survey of bloodstream infection isolates: SENTRY Antimicrobial Surveillance Program in Buenos Aires, Argentina (1997-2002). Rev Panam Infectol 8 (2006) 11-17
29. Tsai T.Y., Chang S.C., Hsueh P.R., Feng N.H., and Wang J.T. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. J Microbiol Immunol Infect 40 (2007) 481-486
30. Infectious Diseases Society of America. Bad bugs, no drugs. As antibiotic discovery stagnates... a public health crisis brews. IDSA; 2004. http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554 [accessed September 8, 2008].
31. Gales A.C., Jones R.N., Turnidge J., Rennie R., and Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 Suppl 2 (2001) S146-S155
32. Jones R.N., Sader H.S., and Beach M.L. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 22 (2003) 551-556
33. Falagas M.E., and Rafailidis P.I. Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. Expert Opin Invest Drugs 17 (2008) 973-981
34. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., and Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32 Suppl 2 (2001) S104-S113
35. Nicolau D.P., Freeman C.D., Belliveau P.P., Nightingale C.H., Ross J.W., and Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39 (1995) 650-655
36. Olsen K.M., Rudis M.I., Rebuck J.A., Hara J., Gelmont D., Mehdian R., et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 32 (2004) 1678-1682
37. Tulkens P.M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 27 Suppl C (1991) 49-61
38. Martinez-Salgado C., Lopez-Hernandez F.J., and Lopez-Novoa J.M. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 223 (2007) 86-98
39. Beauchamp D., and Labrecque G. Chronobiology and chronotoxicology of antibiotics and aminoglycosides. Adv Drug Deliv Rev 59 (2007) 896-903
40. Falagas M.E., and Bliziotis I.A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. Int J Antimicrob Agents 29 (2007) 630-636